These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17105614)

  • 81. Donor profiles: demographic factors and their influence on the donor career.
    Veldhuizen IJ; Doggen CJ; Atsma F; De Kort WL
    Vox Sang; 2009 Aug; 97(2):129-38. PubMed ID: 19508703
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Determinants of repeated blood donation among new and experienced blood donors.
    Godin G; Conner M; Sheeran P; Bélanger-Gravel A; Germain M
    Transfusion; 2007 Sep; 47(9):1607-15. PubMed ID: 17725724
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The relative safety of automated two-unit red blood cell procedures and manual whole-blood collection in young donors.
    Benjamin RJ; Dy BA; Kennedy JM; Notari EP; Eder AF
    Transfusion; 2009 Sep; 49(9):1874-83. PubMed ID: 19538429
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Donation archives and prospective donor-recipient repositories: indispensable tools for monitoring blood safety.
    Allain JP; Busch MP
    Transfusion; 2007 Jul; 47(7):1110-4. PubMed ID: 17581143
    [No Abstract]   [Full Text] [Related]  

  • 85. A paradigm shift in the approach to families for organ donation: honoring patients' wishes versus request for permission in patients with Department of Motor Vehicles donor designations.
    Christmas AB; Mallico EJ; Burris GW; Bogart TA; Norton HJ; Sing RF
    J Trauma; 2008 Dec; 65(6):1507-9; discussion 1509-10. PubMed ID: 19077650
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Complications related to blood donation: a population-based study.
    Sorensen BS; Johnsen SP; Jorgensen J
    Vox Sang; 2008 Feb; 94(2):132-7. PubMed ID: 18028259
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Atrial natriuretic peptide serum concentration decreases in donors undergoing discontinuous plasmapheresis involving a large extracorporeal blood volume.
    Karger R; Halbe M; Giffhorn-Katz S; Katz N; Kretschmer V
    Transfusion; 2007 Sep; 47(9):1717-24. PubMed ID: 17725739
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Additional standards for human blood and blood products; source plasma (human)--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Nov; 46(226):57480-1. PubMed ID: 10253366
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Donor safety in plasmapheresis.
    Lundsgaard-Hansen P
    Dev Biol Stand; 1980; 48():287-95. PubMed ID: 7274560
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Anticoagulation, bleeding, and clotting at donor plasmapheresis.
    Evers J; Taborski U
    J Clin Apher; 2018 Aug; 33(4):538-540. PubMed ID: 29575131
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Maximum donation volumes per session in donor plasmapheresis.
    Karger R; Kretschmer V
    Vox Sang; 2006 Nov; 91(4):350; author reply 351-2. PubMed ID: 17105614
    [No Abstract]   [Full Text] [Related]  

  • 92.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 93.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 5.